Steven Artandi, Director of the Stanford Cancer Institute, shared a paper by Uri Ladabaum et al. on X, adding the following:
“SCI member Uri Ladabaum & others found that 1st gen novel cf-bDNA tests may potentially reduce the incidence and mortality of colorectal cancer compared with no screening, but substantially less profoundly than screening colonoscopy or stool tests.”
Authors: Uri Ladabaum, Ajitha Mannalithara, Robert E. Schoen, Jason A. Dominitz, and David Lieberman.
